Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes in triple-negative breast cancer by glucose restriction and cariporide treatment

ABSTRACT: Gene expression changes in triple-negative breast cancer by glucose restriction and cariporide treatment

PROVIDER: PRJNA1145351 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identification of glucose-regulated lncRNAs in triple-negative breast cancer cells

Project description:To comprehensively identify the glucose-regulated lncRNAs, we have employed ArraryStar LncRNA Microarry discovery platform to detect lncRNA expression in glucose-starved and glucose-stimulated triple-negative breast cancer cells. Differentially expressed LncRNAs with statistical significance were identified through Volcano Plot filtering between two groups.

2019-06-03 | GSE106729 | GEO

Gene expression changes in triple-negative breast cancer by glucose restriction and cariporide treatment

Project description:The cells were treated with a combination of media containing 10 or 5 mM glucose and 0 or 25 μM cariporide for 48 hours. A total of four groups were established: NG (normal glucose), CAR (cariporide), LG (low glucose), and LGCAR (low glucose and cariporide).

2024-11-30 | GSE274176 | GEO

Identification of glucose-regulated lncRNAs in triple-negative breast cancer cells

Project description:Identification of glucose-regulated lncRNAs in triple-negative breast cancer cells

| PRJNA417802 | ENA

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

FOXC1 in triple negative breast cancer

Project description:FOXC1 in triple negative breast cancer

| PRJNA882754 | ENA

Metastasis in triple-negative breast cancer

Project description:Metastasis in triple-negative breast cancer

| PRJNA437929 | ENA

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO